Analysts cheer as AbbVie pays $750M cash to ally itself with Genmab on a pipeline of cancer drugs, with billions more on the table
You can count the R&D execs at AbbVie among the believers in Genmab’s bispecific platform tech.
Moving beyond the Allergan buyout, AbbVie refocused on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.